Update on rifampin, rifabutin, and rifapentine drug interactions

Current Medical Research and Opinion

Volumn 29, Issue 1, 2013, Pages 1-12

  Baciewicz, Anne M ^a   Chrisman, Cary R ^b   Finch, Christopher K ^c   Self, Timothy H ^c  

^a VA Puget Sound Health Care Center   (United States)

^b Methodist Medical Center of Oak Ridge   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Drug interactions; Rifabutin; Rifampin; Rifapentine

Indexed keywords

ALISKIREN; AMBRISENTAN; ANALGESIC AGENT; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ANTIINFECTIVE AGENT; ATENOLOL; ATRASENTAN; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CYCLOSPORIN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOCORTICOID; ITRACONAZOLE; KETOCONAZOLE; METHADONE; MIDAZOLAM; ORAL CONTRACEPTIVE AGENT; PHENYTOIN; PLACEBO; PROPAFENONE; QUINIDINE; RIFABUTIN; RIFAMPICIN; RIFAPENTINE; TACROLIMUS; THEOPHYLLINE; UNINDEXED DRUG;

AREA UNDER THE CURVE; CLINICAL EVALUATION; DATA BASE; DRUG CLEARANCE; DRUG METABOLISM; HUMAN; MAXIMUM PLASMA CONCENTRATION; PHARMACODYNAMICS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT FAILURE; TREATMENT RESPONSE;

ANTI-ARRHYTHMIA AGENTS; ANTIBIOTICS, ANTITUBERCULAR; ANTICHOLESTEREMIC AGENTS; ANTIFUNGAL AGENTS; CONTRACEPTIVES, ORAL; CYTOCHROME P-450 ENZYME SYSTEM; DIGOXIN; DRUG INTERACTIONS; HIV PROTEASE INHIBITORS; HUMANS; ITRACONAZOLE; P-GLYCOPROTEIN; RIFABUTIN; RIFAMPIN; SIMVASTATIN; VERAPAMIL;

EID: 84871364478     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2012.747952     Document Type: Review

References (64)

1. Baciewicz AM, Self TH. Rifampin drug interactions. Arch Intern Med 1984;144:1667-71
2. Baciewicz AM, Self TH, Bekemeyer WR. Update on rifampin drug interactions. Arch Intern Med 1987;147:565-8
3. Borcherding SM, Baciewicz AM, Self TH. Update on rifampin drug interactions II. Arch Intern Med 1992;152:711-16
4. Strayhorn VA, Baciewicz AM, Self TH. Update on rifampin drug interactions III. Arch Intern Med 1997;157:2453-8
5. Finch CK, Chrisman CR, Baciewicz AM, et al. Rifampin and rifabutin drug interactions. Arch Intern Med 2002;162:985-92
6. Baciewicz AM, Chrisman CR, Finch CF, et al. Update on rifampin and rifabutin drug interactions. Am J Med Sci 2008;335:126-36
7. Sterling TR, Villarino E, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 2011;356: 2155-66
8. Vormfelde SV, Brockmöller J, Bauer S, et al. Relative impact of genotype and enzyme induction on the metabolic capacity of CYP2C9 in healthy volunteers. Clin Pharmacol Ther 2009;86:54-61
9. Lamba J, Strom S, Venkataramanan R, et al. MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype. Clin Pharmacol Ther 2006;79:325-38
10. Lilja JJ, Junti-Patinen L, Neuvonen PJ. Effect of rifampicin on the pharma-cokinetics of atenolol. Basic Clin Pharmacol Toxicol 2006;98:555-8
11. Goldberg SV, Hanson D, Peloquin CA. Rifamycin treatment of tuberculosis in a patient receiving atenolol: less interaction with rifabutin than with rifampin (letter). Clin Infect Dis 2003;37:607-8
12. Giessmann T, Modess C, Hecker U, et al. CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects. Clin Pharmacol Ther 2004;75:213-22
13. Tapaninen T, Neuvonen PJ, Niemi M. Rifampicin reduces the plasma concentrations and the renin inhibiting effect of aliskiren. Eur J Clin Pharmacol 2010;66:497-502
14. van Giersbergen PLM, Treiber A, Schneiter R, et al. Inhibitory and inductive effects of rifampin on the pharmacokinetics of bosentan in healthy subjects. Clin Pharmacol Ther 2007;81:414-19
15. Harrison B, Magee MH, Mandagere A, et al. Effects of rifampicin (rifampin) on the pharmacokinetics and safety of ambrisentan in healthy subjects. Clin Drug Invest 2010;30:875-85
16. Xiong H, Carr RA, Locke CS, et al. Dual effects of rifampin on the pharma-cokinetics of atrasentan. J Clin Pharmacol 2007;47:423-9
17. Lau YY, Huang Y, Frassetto L, et al. Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther 2007;81:194-204
18. Backman JT, Luurila H, Neuvonen M, et al. Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. Clin Pharmacol Ther 2005;78:154-67
19. Zhang W, Deng S, Chen X-P, et al. Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: a randomized, single-blind, placebo-controlled, crossover study. Clin Ther 2008;30:1283-9
20. Deng S, Chen XP, Cao D, et al. Effects of a concomitant single dose of rifampicin on the pharmacokinetics of pravastatin in a two-phase, randomized, single-blind, placebo-controlled, crossover study in healthy Chinese male subjects. Clin Ther 2009;31:1256-63
21. Kyrklund C, Backman JT, Neuvonan M, et al. Effect of rifampicin on prava-statin pharmacokinetics in healthy subjects. Br J Clin Pharmacol 2003;57: 181-7
22. Zheng HX, Huang Y, Frassetto LA, et al. Elucidating rifampin's inducing and inhibiting effects on glyburide pharmacokinetics and blood glucose in healthy volunteers: unmasking the differential effects of enzyme induction and transporter inhibition for a drug and its primary metabolite. Clin Pharmacol Ther 2009;85:78-85
23. Cho SK, Yoon JS, Lee MG, et al. Rifampin enhances the glucose-lowering effect of metformin and increases OCT1 mRNA levels in healthy participants. Clin Pharmacol Ther 2011;89:416-21
24. Nieminen TJ, Hagelberg NM, Saari TI, et al. Rifampin greatly reduces the plasma concentration of intravenous and oral oxycodone. Anesthesiology 2009;110:1371-8
25. Noppers I, Olofsen E, Niesters M, et al. Effect of rifampicin on S-ketamine and S-norketamine plasma concentrations in healthy volunteers after intravenous S-ketamine administration. Anesthesiology 2011;114:1435-45
26. McCance-Katz E, Moody DE, Prathikanti S, et al. Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patients. Drug Alcohol Depend 2011;118:326-34
27. Morii H. Chiba M, Konishi H, et al. Failure of pain control using transdermal fentanyl during rifampicin treatment (letter). J Pain Symptom Manage 2007;33:5-6
28. Peritogiannis V, Pappas D, Antoniou K, et al. Clozapine-rifampicin interaction in a patient with pulmonary tuberculosis (letter). Gen Hosp Psychiatry 2007;29:280-2
29. Loboz KK, Gross AS, Williams KM, et al. Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity. Clin Pharmacol Ther 2006;80:75-84
30. Mahatthanatrakul W, Nontaput T, Ridtitid W, et al. Rifampin, a cytochrome P450 3A inducer, decreases plasma concentrations in antipsychotic risper-idone in healthy volunteers. J Clin Pharm Ther 2007;32:161-7
31. Sousa M, Pozniak A, Boffito M. Pharmacokinetics and pharmacodynamics of drug interactions involving rifampicin, rifabutin and antimalarial drugs. J Antimicrob Chemother 2008;62:872-8
32. Hohmann C, Kang EM, Jancel T. Rifampin and posaconazole coadministration leads to decreased serum posaconazole concentrations. Clin Infect Dis 2010;50:939-40
33. Krishna G, Parsons A, Kantesaria B, et al. Evaluation of the pharmacokinetics of posaconazole and rifabutin following co-Administration to healthy men. Curr Med Res Opin 2007;23:545-52
34. Geist MJP, Egerer G, Burhenne J, et al. Induction of voriconazole metabolism by rifampin in a patient with acute myeloid leukemia: importance of interdisciplinary communication to prevent treatment errors with complex medications (letter). Antimicrob Agents Chemother 2007;51:3455-6
35. Egle H, Trittler R, Kummerer K, et al. Linezolid and rifampin: drug interaction contrary to expectations (letter)? Clin Pharmacol Ther 2005;77:451-3
36. Gebhart BC, Barker BC, Markewitz BA. Decreased serum levels in a critically ill patient receiving concomitant linezolid and rifampin. Pharmacotherapy 2007;27:476-9
37. Gandelman K, Zhu T, Fahmi OA, et al. Unexpected effect of rifampin on the pharmacokinetics of linezolid: in silico and in vitro approaches to explain its mechanism. J Clin Pharmacol 2011;51:229-36
38. Weiner M, Burman W, Luo CC, et al. Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin. Antimicrob Agents Chemother 2007;51:2861-6
39. Nijland HMJ, Ruslami R, Suroto J, et al. Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis. Clin Infect Dis 2007;45:1001-7
40. Dooley K, Flexner C, Hackman J, et al. Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations. Antimicrob Agents Chemother 2008;52:4037-42
41. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 1-239. Tables 14-16b. Updated March 27, 2012. Available at http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf [Last accessed 19 April 2012]
42. Xarelto (rivaroxaban). Product information. Titusville, NJ: Janssen Pharmaceuticals, Inc., Dec 2011. Available at: www.xareltohcp.com [Last accessed 9 April 2012]
43. Vakkalagadda B, Frost C, Wang J, et al. Effect of rifampin on the pharmaco-kinetics of apixaban, an oral direct inhibitor of factor Xa. J Clin Pharmacol 2009;49:1124. Abstract 143
44. Blech S, Ebner T, Ludwig-Schwellinger E, et al. The metabolism of and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008;36:386-99
45. Pradaxa (dabigatran etexilate mesylate). Product information. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc., Jan 2012. Available at: www.pradaxa.com [Last accessed 9 April 2012]
46. Brilique (ticagrelor) UK summary of product characteristics. AstraZeneca UK Limited, 2011. Available at: www.brilique.com [Last accessed 10 April 2012]
47. Brilinta (ticagrelor) product information. AstraZeneca, July 2011. Available at: www.brilinta.com [Last accessed 10 April 2012]
48. 12 receptor blockage and inhibition of platelet aggregation after clopidogrel. J Thromb Haemost 2010;8:1820-7
49. Lau WC, Gurbel PA, Watkins PB, et al. Contribution of hepatic cyctochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 2004;109:166-71
50. Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 2003;107:32-7
51. Farid NA, Jakubowski JA, Payne CD, et al. Effect of rifampin on the pharma-cokinetics and pharmacodynamics of prasugrel in healthy male subjects. Curr Med Res Opin 2009;25:1821-9
52. Mori T, Aisa Y, Kato J, et al. Overcoming the effect of rifampin on the tacrolimus metabolism by itraconazole administration in an allogenic hema-topoietic stem cell transplant recipient (letter). Int J Hematol 2010;91:553-4
53. Bhaloo S, Prasad GVR. Severe reduction in the tacrolimus levels with rifampin despite multiple cytochrome P450 inhibitors: a case report. Transplant Proc 2003;35:2449-51
54. Frymoyer A, Shugarts S, Browne M, et al. Effect of a single-dose rifampin on the pharmacokinetics of warfarin in healthy volunteers. Clin Pharmacol Ther 2010;88:540-7
55. Skerjanec A, Wang J, Maren K, et al. Investigation of the pharmacokinetic interactions of deferasirox, a once-daily oral chelator, with midazolam, rifampin, and repaglinide in healthy volunteers. J Clin Pharmacol 2010; 50:205-13
56. Martin P, Oliver S, Robertson J, et al. Pharmacokinetic drug interactions with vandetanib during coadministration with rifampicin or itraconazole. Drugs 2011;11:37-51
57. Nassr N, Huennemeyer A, Herzog R, et al. Effects of rifampicin on the phar-macokinetics of roflumilast and roflumilast N-oxide in healthy subjects. Br J Clin Pharmacol 2009;68:580-7
58. Shin K-H, Kim B-H, Kim T-E, et al. The effects of ketoconazole and rifampicin on the pharmacokinetics of mirodenafil in healthy Korean male volunteers: an open-label, one-sequence, three-period, three-treatment crossover study. Clin Ther 2009;31:3009-20
59. Backman JT, Granfors MT, Neuvonen PJ. Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tiza-nidine and caffeine. Eur J Clin Pharmacol 2006;62:451-61
60. Shon J-H, Yeo C-W, Liu J-H, et al. Itraconazole and rifampin alter significantly the disposition and antihistamine effect of ebastine and its metabolites in healthy participants. J Clin Pharmacol 2010;50:195-204
61. Zhou S, Lim LY, Chowbay B. Herbal modulation of P-glycoprotein. Drug Metab Rev 2004;36:57-104
62. Sharma S, Kumar M, Sharma S, et al. Piperine as an inhibitor of Rv1258c, a putative multidrug efflux pump of Mycobacterium tuberculosis. J Antimicrob Chemother 2010;65:1694-701
63. Vital Durand D, Hampden C, Boobis AR, et al. Induction of mixed function oxidase activity in man by rifapentine (MDL 473), a long-Acting rifamycin derivative. Br J Clin Pharmacol 1986;21:1-7
64. Li AP, Reith MK, Rasmussen A, et al. Primary human hepatocytes as a tool for the evaluation of structure-Activity relationship in cytochrome P450 induction potential of xenobiotics: evaluation of rifampin, rifapentine, and rifabutin. Chem Biol Interact 1997;107:17-30